Stockscreener 앱 받기
2.83
2.54%
0.07
시간 외 거래:
2.83
전일 마감가:
$2.76
열려 있는:
$2.71
하루 거래량:
246.38K
Relative Volume:
0.54
시가총액:
$148.98M
수익:
$2.81M
순이익/손실:
$-97.34M
주가수익비율:
-1.7911
EPS:
-1.58
순현금흐름:
$-91.47M
1주 성능:
-6.29%
1개월 성능:
-21.17%
6개월 성능:
-26.87%
1년 성능:
-68.80%
1일 변동 폭
$2.71
$2.90
1주일 범위
$2.67
$3.145
52주 변동 폭
$2.67
$10.13
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
명칭
Fulcrum Therapeutics Inc
전화
617-651-8851
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
FULC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
2.83 | 148.98M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-09-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2023-09-25 | 개시 | Goldman | Neutral |
| 2023-08-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | 업그레이드 | Stifel | Hold → Buy |
| 2023-05-04 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-02-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 개시 | Goldman | Buy |
| 2022-03-08 | 개시 | Oppenheimer | Outperform |
| 2022-03-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-08-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2020-10-16 | 개시 | Piper Sandler | Overweight |
| 2020-08-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2019-10-03 | 개시 | H.C. Wainwright | Buy |
| 2019-08-12 | 개시 | BofA/Merrill | Buy |
모두보기
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
Fulcrum Therapeutics stock hits 52-week low at $2.77 - Investing.com India
Charles Schwab Investment Management Inc. Lowers Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $8.63 - Defense World
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FULC - Business Wire
Fulcrum Therapeutics stock hits 52-week low at $2.85 By Investing.com - Investing.com Australia
Fulcrum Therapeutics stock hits 52-week low at $2.85 - Investing.com India
Fulcrum Therapeutics at Leerink’s Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com UK
Investors who lost money on Fulcrum Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigationFULC - ACCESS Newswire
Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal - Benzinga
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - The Manila Times
Fulcrum Therapeutics Ends Agreement with MyoKardia By Investing.com - Investing.com South Africa
Fulcrum Therapeutics Ends Agreement with MyoKardia - Investing.com India
Fulcrum Therapeutics Faces Termination of Key Agreement - TipRanks
Fulcrum Therapeutics Inc Myokardia Terminates Collaboration And License Agreement With Co - Marketscreener.com
Will Fulcrum Therapeutics Reveal New Rare Disease Pipeline Updates at Upcoming Leerink Conference? - StockTitan
Fulcrum Therapeutics (NASDAQ:FULC) Issues Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Leerink Partnrs Issues Negative Forecast for FULC Earnings - Defense World
HC Wainwright Has Pessimistic Outlook of FULC Q1 Earnings - Defense World
Fulcrum Therapeutics’ (FULC) Neutral Rating Reiterated at HC Wainwright - Defense World
Fulcrum Therapeutics' (FULC) Neutral Rating Reiterated at HC Wainwright - MarketBeat
Levi & Korsinsky Announces an Investigation on Behalf of Fulcrum Therapeutics, Inc. (FULC) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
What is HC Wainwright's Forecast for FULC FY2029 Earnings? - MarketBeat
FY2029 Earnings Estimate for FULC Issued By HC Wainwright - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of “Hold” from Brokerages - Defense World
Fulcrum Therapeutics’ Earnings Call Highlights Financial Gains - TipRanks
Shareholder Rights Advocates at Levi & Korsinsky Investigate Fulcrum Therapeutics, Inc. (FULC) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Shareholders that lost money on Fulcrum Therapeutics, Inc. (FULC) should contact Levi & Korsinsky about Securities Fraud InvestigationFULC - ACCESS Newswire
Fulcrum Therapeutics (NASDAQ:FULC investor five-year losses grow to 82% as the stock sheds US$28m this past week - Simply Wall St
Lost Money on Fulcrum Therapeutics, Inc.(FULC)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2024 Earnings Call Transcript - Insider Monkey
Fulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 20 - GuruFocus.com
Fulcrum Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FULCRUM THERAPEUTICS Earnings Results: $FULC Reports Quarterly Earnings - Nasdaq
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024 - The Manila Times
Fulcrum Therapeutics, Inc. SEC 10-K Report - TradingView
Fulcrum Therapeutics Reports Q4 and Full Year 2024 Financial Results and Updates on Pioneering SCD Trial - Nasdaq
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth - The Bakersfield Californian
Can Fulcrum's Improved Financials and Sickle Cell Trial Progress Attract Biotech Investors? - StockTitan
Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 2024 Result - Yahoo Finance
Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Tuesday - Defense World
Fulcrum Therapeutics, Inc. Being Investigated on Behalf of Fulcrum Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details. - ACCESS Newswire
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Down 7.3% in January - MarketBeat
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET - The Manila Times
Fulcrum Therapeutics, Inc. Scheduled to Release Q4 and Full Year 2024 Financial Results on February 25, 2025 - Nasdaq
Rare Disease Pioneer Fulcrum Sets Stage for Major 2024 Financial Revelation - StockTitan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum: Next Set Of SCD Data Is Crucial For Continued Pipeline Advancement - Seeking Alpha
Fulcrum (FULC) Issues Strategic Employee Stock Options PackageKey Details Revealed - StockTitan
Fulcrum Therapeutics Inc (FULC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):